ORIGINAL ARTICLE
Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients
1
Pathology Department, National Liver Institute, Menoufia University, Menoufia, Egypt
2
Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Menofia, Egypt
3
Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Menofia, Egypt
4
Hepato-pancreaticobiliary Surgery, National Liver Institute, Menoufia University, Menofia, Egypt
Submission date: 2021-09-15
Final revision date: 2022-04-04
Acceptance date: 2022-04-05
Publication date: 2022-08-10
Pol J Pathol 2022;73(2):88-98
KEYWORDS
TOPICS
ABSTRACT
The pathogenesis of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) differs according to whether prior treatment with interferon (IFN) vs. direct-acting antiviral agents (DAAs) was administered. Cyclo- oxygenase-2 (COX-2), yes-associated protein 1 (YAP), and transcriptional co-activator with PDZ-binding motif (TAZ) play a crucial role in hepatocarcinogenesis. However, their roles in untreated or treated HCV-related HCC development have not been clarified.
Therefore, we performed an immunohistochemical study and stained tissue from 83 HCV-related HCC cases using antibodies against COX-2, YAP, and TAZ and correlated their expression with the clinicopathological characteri stics and survival data.
The cases were subdivided into 3 groups based on prior HCV treatment. In the 3 groups, COX-2 was significantly higher in HCC tissue compared with adjacent non-tumour liver tissue. However, the expression of YAP/TAZ was not significantly different between HCC and adjacent non-tumour tissue. We further grouped HCC cases into YAP+/TAZ+ and YAP–/TAZ– cases.
In the YAP+/TAZ+ cases, COX-2 was significantly associated with tumour size, tumour multifocality, and late pathologic stage. No significant difference was observed in COX-2 and TAZ expression as a result of IFN or DAA treatment; however, YAP was significantly higher in IFN-treated HCC. Cyclo-oxygenase-2 overexpression may play a role in late HCC development, while YAP/TAZ could play an early role in HCC progression. Sustained expression of combined YAP/TAZ could mediate the poor prognostic role of COX-2.
Therefore, we performed an immunohistochemical study and stained tissue from 83 HCV-related HCC cases using antibodies against COX-2, YAP, and TAZ and correlated their expression with the clinicopathological characteri stics and survival data.
The cases were subdivided into 3 groups based on prior HCV treatment. In the 3 groups, COX-2 was significantly higher in HCC tissue compared with adjacent non-tumour liver tissue. However, the expression of YAP/TAZ was not significantly different between HCC and adjacent non-tumour tissue. We further grouped HCC cases into YAP+/TAZ+ and YAP–/TAZ– cases.
In the YAP+/TAZ+ cases, COX-2 was significantly associated with tumour size, tumour multifocality, and late pathologic stage. No significant difference was observed in COX-2 and TAZ expression as a result of IFN or DAA treatment; however, YAP was significantly higher in IFN-treated HCC. Cyclo-oxygenase-2 overexpression may play a role in late HCC development, while YAP/TAZ could play an early role in HCC progression. Sustained expression of combined YAP/TAZ could mediate the poor prognostic role of COX-2.
REFERENCES (41)
1.
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Ro- berts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16: 589-604.
2.
Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161-176.
3.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England) 2018; 391: 1301-1314.
4.
Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med 2009; 360: 1899-1901.
5.
Fehily SR, Papaluca T, Thompson AJ. Long-term impact of direct-acting antiviral agent therapy in HCV cirrhosis: critical review. Semin Liver Dis 2019; 39: 341-353.
6.
Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. J Hepatocell Carcinoma 2020; 7: 45-76.
7.
Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol 2019; 234: 5683-5699.
8.
Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (-TRCP). Genes Dev 2010; 24: 72-85.
9.
Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 2014; 141: 1614-1626.
10.
Li W, Cao Y, Xu J, et al. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer. J Exp Clin Cancer Res 2017; 36: 144.
11.
Xu G, Wang Y, Li W, et al. COX-2 forms regulatory loop with YAP to promote proliferation and tumorigenesis of hepatocellular carcinoma cells. Neoplasia 2018; 20: 324-334.
12.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188.
14.
Li C, Yang W, Zhang J, et al. SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma. Int J Mol Sci 2014; 15: 7124-7138.
15.
Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003; 9: 2651-2656.
16.
Van Haele M, Moya IM, Karaman R, et al. YAP and TAZ hete- rogeneity in primary liver cancer: an analysis of its prognostic and diagnostic role. Int J Mol Sci 2019; 20: 638.
17.
Chen G, Li X, Yang J, et al. Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis. Arch Med Sci 2016; 12: 1110-1117.
18.
El Fayoumie M, Abdelhady M, Gawish A, et al. Changing patterns of hepatocellular carcinoma after treatment with direct antiviral agents. Gastrointest Tumors 2020; 7: 50-60.
19.
Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues – is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med 2009; 13: 3753-5763.
20.
Chen WC, Tseng CK, Chen YH, et al. HCV NS5A up-regulates COX-2 expression via IL-8-mediated activation of the ERK/JNK MAPK pathway. PLoS One 2015; 10: e0133264.
21.
Yimlamai D, Christodoulou C, Galli GG, et al. Hippo pathway activity influences liver cell fate. Cell 2014; 157: 1324-1338.
22.
Abdallah RA, Shaban MI, Taie DM, Asaad NY, Badr A. relation between immunohistochemical expression of hippo pathway effectors and chronic hepatitis induced fibrosis in Egyptian patients. Turk Patoloji Derg 2020; 36: 48-63.
23.
Yu HX, Yao Y, Bu FT, et al. Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells. Mol Immunol 2019; 107: 29-40.
24.
Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001; 7: 1410-1418.
25.
Wang S, Zhou L, Ling L, et al. The crosstalk between hippo-YAP pathway and innate immunity. Front Immunol 2020; 11: 323.
26.
Han S, Bai E, Jin G, et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res 2014; 2014: 261365.
27.
Moya IM, Castaldo SA, Mooter L, et al. Peritumoral activation of the hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science 2019; 366: 1029-1034.
28.
Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol 2009; 62: 690-693.
29.
Bai N, Zhang C, Liang N, et al. Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther 2013; 14: 511-520.
30.
Jie L, Fan W, Weiqi D, et al. The hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract 2013; 2013: 187070.
31.
Llorente-Izquierdo C, Mayoral R, Cucarella C, et a. Progression of liver oncogenesis in the double transgenic mice c-myc/TGF is not enhanced by cyclooxygenase-2 expression. Prostaglandins Other Lipid Mediat 2013; 106: 106-115.
32.
Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006; 9: 6-8.
33.
Nu¼ez F, Bravo S, Cruzat F, Montecino M, de Ferrari GV. Wnt/-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells. PLoS One 2011; 6: e18562.
34.
Guerrant W, Kota S, Troutman S, et al. YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2-EGFR signaling axis. Cancer Res 2016; 76: 3507-3519.
35.
Zhang W, Nandakumar N, Shi Y, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 2014; 7: ra42.
36.
Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, et al. YAP1 and COX2 coordinately regulate urothelial cancer stem-like cells. Cancer Res 2018; 78: 168-181.
37.
Dai P, Li J, Ma XP, Huang J, Meng JJ, Gong P. Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther 2018; 11: 721-730.
38.
Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics 2020; 10: 3622-3635.
39.
Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240.
40.
Liu L, Ho RLK, Chen GG, Lai PBS. Sorafenib inhibits hypoxia- inducible factor-1 synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 2012; 18: 5662-5671.
41.
Dong XF, Liu TQ, Zhi XT, et al. COX-2/PGE2 axis regulates HIF2 activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment. Clin Cancer Res 2018; 24: 3204-3216.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
